APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Monoclonal Antibody Biologics and Biosimilars Market Outlook and Growth Opportunities 2026

21 December 2025193 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody Biologics and Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody Biologics and Biosimilars Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody Biologics and Biosimilars Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody Biologics and Biosimilars Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Monoclonal Antibody Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Monoclonal Antibody Biologics and Biosimilars market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Monoclonal Antibody Biologics and Biosimilars market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody Biologics and Biosimilars and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody Biologics and Biosimilars revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Monoclonal Antibody Biologics and Biosimilars market.

Monoclonal Antibody Biologics and Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Biogen

Amgen

AbbVie

Sobi

Innovent Biologics

Celltrion

3SBIO

Monoclonal Antibody Biologics and Biosimilars Segment by Type

Biologics

Biosimilars

Monoclonal Antibody Biologics and Biosimilars Segment by Application

Cancer

Autoimmune Disease

Other

Monoclonal Antibody Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Monoclonal Antibody Biologics and Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Monoclonal Antibody Biologics and Biosimilars key companies, revenue, market share, and recent developments.

3. To split the Monoclonal Antibody Biologics and Biosimilars breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Monoclonal Antibody Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Monoclonal Antibody Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Monoclonal Antibody Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monoclonal Antibody Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Monoclonal Antibody Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Monoclonal Antibody Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Monoclonal Antibody Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibody Biologics and Biosimilars Industry Trends Table 2. Monoclonal Antibody Biologics and Biosimilars Industry Drivers Table 3. Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges Table 4. Monoclonal Antibody Biologics and Biosimilars Industry Restraints Table 5. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibody Biologics and Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Monoclonal Antibody Biologics and Biosimilars Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Monoclonal Antibody Biologics and Biosimilars Key Company Manufacturing Base & Headquarters Table 9. Global Monoclonal Antibody Biologics and Biosimilars Company, Product Type & Application Table 10. Global Monoclonal Antibody Biologics and Biosimilars Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Monoclonal Antibody Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Biologics Table 15. Significant Companies of Biosimilars Table 16. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type (2021-2026) Table 20. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Autoimmune Disease Table 23. Significant Companies of Other Table 24. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application (2021-2026) Table 28. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application (2027-2032) Table 29. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Region (2021-2026) Table 32. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Region (2027-2032) Table 34. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Market Share by Country (2021-2026) Table 37. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Market Share by Country (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 43. Sanofi Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 58. Merck Recent Development Table 59. Roche Company Information Table 60. Roche Business Overview Table 61. Roche Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 63. Roche Recent Development Table 64. Eli Lilly Company Information Table 65. Eli Lilly Business Overview Table 66. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 68. Eli Lilly Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 73. Pfizer Recent Development Table 74. Biogen Company Information Table 75. Biogen Business Overview Table 76. Biogen Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 78. Biogen Recent Development Table 79. Amgen Company Information Table 80. Amgen Business Overview Table 81. Amgen Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 83. Amgen Recent Development Table 84. AbbVie Company Information Table 85. AbbVie Business Overview Table 86. AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 88. AbbVie Recent Development Table 89. Sobi Company Information Table 90. Sobi Business Overview Table 91. Sobi Monoclonal Antibody Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 93. Sobi Recent Development Table 94. Innovent Biologics Company Information Table 95. Innovent Biologics Business Overview Table 96. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 98. Innovent Biologics Recent Development Table 99. Celltrion Company Information Table 100. Celltrion Business Overview Table 101. Celltrion Monoclonal Antibody Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 103. Celltrion Recent Development Table 104. 3SBIO Company Information Table 105. 3SBIO Business Overview Table 106. 3SBIO Monoclonal Antibody Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 108. 3SBIO Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Monoclonal Antibody Biologics and Biosimilars Product Image Figure 2. Global Monoclonal Antibody Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibody Biologics and Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Biologics Image Figure 8. Biosimilars Image Figure 9. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Autoimmune Disease Image Figure 14. Other Image Figure 15. Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application (2021-2032) Figure 18. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 21. North America Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 27. South America Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Cancer
  • Autoimmune Disease
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Biogen
  • Amgen
  • AbbVie
  • Sobi
  • Innovent Biologics
  • Celltrion
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Monoclonal Antibody Biologics and Biosimilars Market Dynamics
  1. 2.1 Monoclonal Antibody Biologics and Biosimilars Industry Trends
  2. 2.2 Monoclonal Antibody Biologics and Biosimilars Industry Drivers
  3. 2.3 Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody Biologics and Biosimilars Industry Restraints
3 Monoclonal Antibody Biologics and Biosimilars Market by Company
  1. 3.1 Global Monoclonal Antibody Biologics and Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Monoclonal Antibody Biologics and Biosimilars Company Ranking (2024-2026)
  4. 3.4 Global Monoclonal Antibody Biologics and Biosimilars Company Manufacturing Base and Headquarters
  5. 3.5 Global Monoclonal Antibody Biologics and Biosimilars Company Product Type and Application
  6. 3.6 Global Monoclonal Antibody Biologics and Biosimilars Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Monoclonal Antibody Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Monoclonal Antibody Biologics and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Monoclonal Antibody Biologics and Biosimilars Market by Type
  1. 4.1 Monoclonal Antibody Biologics and Biosimilars Type Introduction
  2. 4.1.1 Biologics
  3. 4.1.2 Biosimilars
  4. 4.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type
  5. 4.2.1 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Type (2021-2032)
  7. 4.2.3 Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type (2021-2032)
5 Monoclonal Antibody Biologics and Biosimilars Market by Application
  1. 5.1 Monoclonal Antibody Biologics and Biosimilars Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Autoimmune Disease
  4. 5.1.3 Other
  5. 5.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application
  6. 5.2.1 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Application (2021-2032)
  8. 5.2.3 Global Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application (2021-2032)
6 Monoclonal Antibody Biologics and Biosimilars Regional Value Analysis
  1. 6.1 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Region: 2021-2026
  4. 6.2.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032)
  7. 6.3.2 North America Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032)
  10. 6.4.2 Europe Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032)
  16. 6.6.2 South America Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Monoclonal Antibody Biologics and Biosimilars Country-level Value Analysis
  1. 7.1 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country (2021-2032)
  3. 7.2.1 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country (2021-2026)
  4. 7.2.2 Global Monoclonal Antibody Biologics and Biosimilars Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Monoclonal Antibody Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Monoclonal Antibody Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Biogen
  44. 8.8.1 Biogen Company Information
  45. 8.8.2 Biogen Business Overview
  46. 8.8.3 Biogen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  48. 8.8.5 Biogen Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 Sobi
  62. 8.11.1 Sobi Company Information
  63. 8.11.2 Sobi Business Overview
  64. 8.11.3 Sobi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  66. 8.11.5 Sobi Recent Developments
  67. 8.12 Innovent Biologics
  68. 8.12.1 Innovent Biologics Company Information
  69. 8.12.2 Innovent Biologics Business Overview
  70. 8.12.3 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  72. 8.12.5 Innovent Biologics Recent Developments
  73. 8.13 Celltrion
  74. 8.13.1 Celltrion Company Information
  75. 8.13.2 Celltrion Business Overview
  76. 8.13.3 Celltrion Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  78. 8.13.5 Celltrion Recent Developments
  79. 8.14 3SBIO
  80. 8.14.1 3SBIO Company Information
  81. 8.14.2 3SBIO Business Overview
  82. 8.14.3 3SBIO Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  83. 8.14.4 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  84. 8.14.5 3SBIO Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst